TRU: FY26 sales projected to surpass NZ$2.8m as public programs and new markets accelerate growth

About this update from Truscreen Group Ltd.

AI-driven cervical cancer screening device achieved FY25 sales of NZ$1.7m, with China as the dominant market. FY26 sales are forecast to exceed NZ$2.8m, driven by new public screening programs, expanded distribution, and a strategic alliance with Dalton Bio for HPV DNA tests.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Truscreen Group Ltd.